Pacific Edge's APAC Business Progresses Toward Profitability on Higher Commercial Test Volumes

MT Newswires Live

07/14

Pacific Edge (ASX:PEB, NZE:PEB) said its Asia-Pacific (APAC) operations are progressing toward profitability on a direct-cost basis, supported by higher commercial test volumes and gaining adoption of the Cxbladder Triage Plus test, according to a Tuesday filing with the Australian and New Zealand bourses.

The company said its APAC commercial test volume rose nearly 13% in the first quarter of fiscal year 2027 to 1,158 tests from 1,026 tests in the fourth quarter of fiscal year 2026.

Meanwhile, APAC business revenue of NZ$2 million represented 19% of overall operating revenue in the second half of fiscal year 2026, up from 8% in fiscal 2025, the company said.

In the US, commercial test volume fell 2.4% in the first quarter of fiscal year 2027 to 3,295 from 3,375 in the fourth quarter of fiscal year 2026 amid continuing attrition in the sales team, Pacific Edge said.

The company's New Zealand shares gained 2% in recent Tuesday trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2651405821"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2651405821\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2651405821?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 08:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651405821","market":"nz","top_or_hot":-1,"title":"Pacific Edge's APAC Business Progresses Toward Profitability on Higher Commercial Test Volumes","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PFGTF\">Pacific Edge</a> (ASX:PEB, NZE:PEB) said its Asia-Pacific (APAC) operations are progressing toward profitability on a direct-cost basis, supported by higher commercial test volumes and gaining adoption of the Cxbladder Triage Plus test, according to a Tuesday filing with the Australian and New Zealand bourses.</p><p>The company said its APAC commercial test volume rose nearly 13% in the first quarter of fiscal year 2027 to 1,158 tests from 1,026 tests in the fourth quarter of fiscal year 2026.</p><p>Meanwhile, APAC business revenue of NZ$2 million represented 19% of overall operating revenue in the second half of fiscal year 2026, up from 8% in fiscal 2025, the company said.</p><p>In the US, commercial test volume fell 2.4% in the first quarter of fiscal year 2027 to 3,295 from 3,375 in the fourth quarter of fiscal year 2026 amid continuing attrition in the sales team, <a href=\"https://laohu8.com/S/PEB.AU\">Pacific Edge</a> said.</p><p>The company's New Zealand shares gained 2% in recent Tuesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pacific Edge's APAC Business Progresses Toward Profitability on Higher Commercial Test Volumes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPacific Edge's APAC Business Progresses Toward Profitability on Higher Commercial Test Volumes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-14 08:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PFGTF\">Pacific Edge</a> (ASX:PEB, NZE:PEB) said its Asia-Pacific (APAC) operations are progressing toward profitability on a direct-cost basis, supported by higher commercial test volumes and gaining adoption of the Cxbladder Triage Plus test, according to a Tuesday filing with the Australian and New Zealand bourses.</p><p>The company said its APAC commercial test volume rose nearly 13% in the first quarter of fiscal year 2027 to 1,158 tests from 1,026 tests in the fourth quarter of fiscal year 2026.</p><p>Meanwhile, APAC business revenue of NZ$2 million represented 19% of overall operating revenue in the second half of fiscal year 2026, up from 8% in fiscal 2025, the company said.</p><p>In the US, commercial test volume fell 2.4% in the first quarter of fiscal year 2027 to 3,295 from 3,375 in the fourth quarter of fiscal year 2026 amid continuing attrition in the sales team, <a href=\"https://laohu8.com/S/PEB.AU\">Pacific Edge</a> said.</p><p>The company's New Zealand shares gained 2% in recent Tuesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PEB.NZ","symbol_name":"Pacific Edge Limited Ordinary Shares","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2651405821","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651405821","pubTimestamp":1783987753,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pacific Edge  said its Asia-Pacific  operations are progressing toward profitability on a direct-cost basis, supported by higher commercial test volumes and gaining adoption of the Cxbladder Triage Plus test, according to a Tuesday filing with the Australian and New Zealand bourses.The company said its APAC commercial test volume rose nearly 13% in the first quarter of fiscal year 2027 to 1,158 tests from 1,026 tests in the fourth quarter of fiscal year 2026.Meanwhile, APAC business revenue of NZ$2 million represented 19% of overall operating revenue in the second half of fiscal year 2026, up from 8% in fiscal 2025, the company said.In the US, commercial test volume fell 2.4% in the first quarter of fiscal year 2027 to 3,295 from 3,375 in the fourth quarter of fiscal year 2026 amid continuing attrition in the sales team, Pacific Edge said.The company's New Zealand shares gained 2% in recent Tuesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PEB.NZ":"Pacific Edge Limited Ordinary Shares","BK7067":"生物科技","BK8033":"生物科技","PEB.AU":"PACIFIC EDGE LTD","APAC":"Stonebridge Acquisition Corp"},"translate_title":"Pacific Edge 的 APAC 业务凭借更高的商业测试量实现盈利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APAC":1.5,"PEB.NZ":1.5,"PEB.AU":1},"content_text":"Pacific Edge (ASX:PEB, NZE:PEB) said its Asia-Pacific (APAC) operations are progressing toward profitability on a direct-cost basis, supported by higher commercial test volumes and gaining adoption of the Cxbladder Triage Plus test, according to a Tuesday filing with the Australian and New Zealand bourses.The company said its APAC commercial test volume rose nearly 13% in the first quarter of fiscal year 2027 to 1,158 tests from 1,026 tests in the fourth quarter of fiscal year 2026.Meanwhile, APAC business revenue of NZ$2 million represented 19% of overall operating revenue in the second half of fiscal year 2026, up from 8% in fiscal 2025, the company said.In the US, commercial test volume fell 2.4% in the first quarter of fiscal year 2027 to 3,295 from 3,375 in the fourth quarter of fiscal year 2026 amid continuing attrition in the sales team, Pacific Edge said.The company's New Zealand shares gained 2% in recent Tuesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}